The goal of the ILIAD protocol is to create a database and bank of biological specimens (DNA, plasma, lymphocytes) from individuals with severe drug-induced liver injury (DILI) due to isoniazid (INH), phenytoin (Dilantin®), amoxicillin/clavulanate (Augmentin®), minocycline, nitrofurantoin, trimethroprim/sulfamethoxazole (Bactrim®), or valproic acid (Depakote®), after January 1, 1994. This study is funded by the NIH/NIDDK.
Contacts for referrals or questions: see below
The goal of this multicenter NIH study is to prospectively identify bona fide cases of liver injury due to drugs and complementary and alternative medications (CAM) within 6 months of onset. Clinical data, blood, DNA, and urine will be collected from affected patients and matched controls for mechanistic and genetic studies.
Principal Investigator: Robert Fontana, MD firstname.lastname@example.org
Angela Liu, MPH (734) 936-4886 email@example.com
Kristin Chesney, MBA (734) 936-4886 firstname.lastname@example.org
Sophana Mao, BS (734) 936-4886 email@example.com
Drug-Induced Liver Injury Network: http://dilin.dcri.duke.edu/index.html
NIH funds network to study drug-induced liver injury: http://www.nih.gov/news/pr/nov2004/niddk-19.htm
NIDDK LiverTox web site: http://www.livertox.nih.gov/